Cargando…

Impact of SARS-CoV-2 infection on Gaucher disease patients in Italy

Detalles Bibliográficos
Autores principales:	Cappellini, Maria Domenica, Barbato, Antonio, Carubbi, Francesca, Di Rocco, Maja, Giona, Fiorina, Giuffrida, Gaetano, Linari, Silvia, Quarta, Antonella, Scarpa, Maurizio, Spada, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849465/ http://dx.doi.org/10.1016/j.ymgme.2020.12.033

Ejemplares similares

Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
por: Di Rocco, Maja, et al.
Publicado: (2020)

Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications
por: Linari, Silvia, et al.
Publicado: (2022)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

GAU-PED study for early diagnosis of Gaucher disease in children with splenomegaly and cytopenia
por: Pession, Andrea, et al.
Publicado: (2023)

Accurate Molecular Diagnosis of Gaucher Disease Using Clinical Exome Sequencing as a First-Tier Test
por: Zampieri, Stefania, et al.
Publicado: (2021)

The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO)
por: Tullo, Maria Giulia, et al.
Publicado: (2023)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia
por: Motta, Irene, et al.
Publicado: (2021)

Bone turnover markers in patients with type 1 Gaucher disease
por: Giuffrida, Gaetano, et al.
Publicado: (2012)

Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease1
por: Hughes, Derralynn, et al.
Publicado: (2007)

Coxarthritis as the Presenting Symptom of Gaucher Disease Type 1
por: Brisca, Giacomo, et al.
Publicado: (2011)

Screening for lysosomal diseases in a selected pediatric population: the case of Gaucher disease and acid sphingomyelinase deficiency
por: Di Rocco, Maja, et al.
Publicado: (2023)

A case of motor neuron involvement in Gaucher disease
por: Pozzilli, V., et al.
Publicado: (2019)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2016)

Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment
por: Iaccarino Idelson, Paola, et al.
Publicado: (2022)

Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report
por: Giuffrida, Gaetano, et al.
Publicado: (2016)

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
por: Giuffrida, Gaetano, et al.
Publicado: (2023)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

SARS-CoV-2 Infection in Children in Southern Italy: A Descriptive Case Series
por: Loconsole, Daniela, et al.
Publicado: (2020)

Gaucher: A Systematic Review on Oral and Radiological Aspects
por: Minervini, Giuseppe, et al.
Publicado: (2023)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Gaucher-Associated Parkinsonism
por: Li, Yaqiong, et al.
Publicado: (2015)

Gaucher disease: an update
por: Dumitrascu, Dan L.
Publicado: (2021)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
por: Schiavoni, Mario, et al.
Publicado: (2019)

PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
por: Symeonidis, Argiris, et al.
Publicado: (2023)

Longitudinal investigation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in older patients in the province of Palermo (Southern Italy) during the early wave of the pandemic
por: Matranga, Domenica, et al.
Publicado: (2021)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology
por: Ormazabal, Maximiliano Emanuel, et al.
Publicado: (2023)

Enzyme Replacement in Gaucher Disease
por: Beutler, Ernest
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_tbsrajir2au3q2ms2rjr37gp5a